Where would you like to go?
Please contact customer service to place an order.
Please contact accounting at (800) 647-6100 to place an order.
You were in the middle of creating an order for Patient . Do you want to go back to that order or finish working with this patient?
Call Us: 1 (800) 647 6100
6900 Kingspointe Pkwy, Orlando, FL 32819, US
Open in Google Maps
I don't have a referral code
Note: You must be linked to a practitioner before ordering XYMOGEN formulas. Don't have one? We can help. Click "Find a Practitioner" to choose one and place an order.
I'm a New Customer
People First Culture
Orlando-based health sciences company XYMOGEN has recently been recognized for the tenth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation
XYMOGEN is way ahead of the supplements transparency curve. Recently, Amazon Elements, the mega internet retailer’s private label brand, has included four dietary supplements, in an effort, it states, to bring more transparency and safety to these products. As the only exclusive practitioner-channel supplements formula company, XYMOGEN has been offering this transparency to its customers for years.
XYMOGEN, in partnership with FON Consulting, publishes a chronicle of the dramatic rise and influence of integrative healthcare.
ORLANDO, Fla. — October 4, 2016 — XYMOGEN® rocks the nutraceutical industry yet again with the introduction of its patented and exclusive MonoPure™ line of omega-3 EPA + DHA products. What makes MonoPure™ so different from other omega-3 EPA + DHA products is that it delivers an easy to digest highly concentrated omega-3 fish oil, which when studied clinically was shown to be three times more absorbable* than ethyl ester (EE) fish oil.
ORLANDO, Fla. (September 27, 2016)—XYMOGEN is proud to announce that it has been chosen by Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to manufacture and supply the oral vitamin and mineral preparations that will be tested in the second Trial to Assess Chelation Therapy (TACT2), a $37M federally sponsored clinical trial.
Orlando, FL. – September 22, 2016 – Orlando-based health sciences company XYMOGEN has recently been recognized for the ninth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation.
Join our mailing list.
Interested in receiving special offers, access to exclusive webinars, seminars, up-to-date industry news, and so much more? Sign up for our FREE newsletter and get started today!
BONUS: As a XYMOGEN Insider, you will also get a FREE digital copy of The Rise of Integrative Health & Medicine—The Milestones: 1963–Present by Glenn Sabin and Taylor Walsh.
We at XYMOGEN, are committed to respecting your online privacy and recognize your need for appropriate protection and management of any personally identifiable information ("Personal Information") you share with us.
Personal Information means any information that may be used to identify an individual, including, but not limited to, a first and last name, a home or other physical address and an email address or other contact information, whether at work or at home. In general, you can visit XYMOGEN's Web pages without telling us who you are or revealing any Personal Information about yourself.
If you choose to provide us with your Personal Information on the Web, we may transfer that Information within XYMOGEN or to XYMOGEN's third-party service providers, across borders, and from your country or jurisdiction to other countries or jurisdictions around the world.
Where XYMOGEN collects Personal Information on the web, we intend to post a purpose statement that explains why Personal Information will be collected and whether we plan to share such Personal Information outside of XYMOGEN or those working on XYMOGEN's behalf. XYMOGEN does not intend to transfer Personal Information without your consent to third parties who are not bound to act on XYMOGEN's behalf unless such transfer is legally required.
You may choose whether or not to provide Personal Information to XYMOGEN. The notice we intend to provide where XYMOGEN collects Personal Information on the Web should help you to make this choice. If you choose not to provide the Personal Information we request, you can still visit most of XYMOGEN's Web sites, but you may be unable to access certain options, offers, and services that involve our interaction with you.
If you chose to have a relationship with XYMOGEN, such as a contractual or other business relationship or partnership, we will naturally continue to contact you in connection with that business relationship.
Wherever your Personal Information may be held within XYMOGEN or on its behalf, we intend to take reasonable and appropriate steps to protect the Personal Information that you share with us from unauthorized access or disclosure.
To the extent that you do provide us with Personal Information, XYMOGEN wishes to maintain accurate Personal Information. Where we collect Personal Information from you on the Web, our goal is to provide a means of contacting XYMOGEN should you need to update or correct that Information. If for any reason those means are unavailable or inaccessible, you may send updates and corrections about your Personal Information to privacy@XYMOGEN.com and we will make reasonable efforts to incorporate the changes in your Personal Information that we hold as soon as practicable.
Third parties provide certain services available on XYMOGEN.com on XYMOGEN's behalf. XYMOGEN may provide information, including Personal Information, that XYMOGEN collects on the Web to third-party service providers to help us deliver programs, products, information, and services. Service providers are also an important means by which XYMOGEN maintains its Web site and mailing lists. XYMOGEN will take reasonable steps to ensure that these third-party service providers are obligated to protect Personal Information on XYMOGEN's behalf.
XYMOGEN does not intend to transfer Personal Information without your consent to third parties who are not bound to act on XYMOGEN's behalf unless such transfer is legally required. Similarly, it is against XYMOGEN's policy to sell Personal Information collected online without consent.
XYMOGEN.com is not structured to attract children. Accordingly, we do not intend to collect Personal Information from anyone we know to be under 13 years of age.
We are committed to privacy and, through our membership in the Online Privacy Alliance, are actively involved in and support current industry initiatives to preserve individual privacy rights on the Internet. Protecting your privacy online is an evolving area, and XYMOGEN's Web sites are constantly evolving to meet these demands.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.